



(12) Translation of
European patent specification

(11) NO/EP 2635299 B1

NORWAY

(19) NO
(51) Int Cl.
A61P 17/14 (2006.01)

Norwegian Industrial Property Office

| | | |
|------|--|---|
| (21) | Translation Published | 2019.12.02 |
| (80) | Date of The European Patent Office Publication of the Granted Patent | 2019.07.31 |
| (86) | European Application Nr. | 11838771.1 |
| (86) | European Filing Date | 2011.11.02 |
| (87) | The European Application's Publication Date | 2013.09.11 |
| (30) | Priority | 2010.11.02, US, 409509 P |
| (84) | Designated Contracting States: | AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR |
| (73) | Proprietor | The Trustees of Columbia University in the City of New York, 412 Low Memorial Library 535 West 116th Street, New York, NY 10027, USA |
| (72) | Inventor | CHRISTIANO, Angela, M., 2 Surrey Lane, Mahwah, NJ 07430, USA CLYNES, Raphael, 231 Van Houten Fields, West Nyack, NY 10994, USA |
| (74) | Agent or Attorney | TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge |

| | | |
|------|-------------------|---|
| (54) | Title | METHODS FOR TREATING HAIR LOSS DISORDERS |
| (56) | References Cited: | EP-A1- 1 176 140 US-A1- 2003 044 803 WO-A1-2010/093808 SUMMARY OF THE 2010 ALOPECIA AREATA CLINICAL/TRANSLATIONAL RESEARCH SUMMIT. 22 October 2010, XP055106797 Retrieved from the Internet: <URL: http://www.naaf.org/site/PageServer?pa_genome=2010 > [retrieved on 2012-02-16] Yann F. Mahe ET AL: "Androgenetic alopecia and microinflammation", INTERNATIONAL JOURNAL OF DERMATOLOGY, vol. 39, no. 8, 1 August 2000 (2000-08-01) , pages 576-584, XP055096339, UK ISSN: 0011-9059, DOI: 10.1046/j.1365-4362.2000.00612.x DELAMERE F M ET AL: "Interventions for alopecia areata.", THE COCHRANE DATABASE OF SYSTEMATIC REVIEWS 2008, no. 2, 2008, page CD004413, XP009182992, ISSN: 1469-493X ITO TAISUKE ET AL: "Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack.", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY MAY 2008, vol. 128, no. 5, May 2008 (2008-05), pages 1196-1206, XP002736854, ISSN: 1523-1747 |

HORNG TIFFANY ET AL: "NKG2D signaling is coupled to the interleukin 15 receptor signaling pathway.", NATURE IMMUNOLOGY DEC 2007, vol. 8, no. 12, December 2007 (2007-12), pages 1345-1352, XP002736855, ISSN: 1529-2916

XING LUZHOU ET AL: "Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition", NATURE MEDICINE, vol. 20, no. 9, 17 August 2014 (2014-08-17), pages 1043-1049, XP002736857, ISSN: 1078-8956

HAREL SIVAN ET AL: "Pharmacologic inhibition of JAK-STAT signaling promotes hair growth.", SCIENCE ADVANCES OCT 2015, vol. 1, no. 9, October 2015 (2015-10), page e1500973,

HORDINSKY MARIA K: "Treatment of alopecia areata: "What is new on the horizon?".", DERMATOLOGIC THERAPY 2011 MAY-JUN, vol. 24, no. 3, May 2011 (2011-05), pages 364-368, XP002736856, ISSN: 1529-8019

CAILLAT-ZUCMAN ET AL: "How NKG2D Ligands Trigger Autoimmunity?", HUMAN IMMUNOLOGY, NEW YORK, NY, US, vol. 67, no. 3, 1 March 2006 (2006-03-01), pages 204-207, XP024993277, ISSN: 0198-8859, DOI: 10.1016/J.HUMIMM.2006.02.013 [retrieved on 2006-03-01]

PETUKHOVA LYNN ET AL: "Genome-wide association study in alopecia areata implicates both innate and adaptive immunity.", NATURE 1 JUL 2010, vol. 466, no. 7302, 1 July 2010 (2010-07-01), pages 113-117, XP002736853, ISSN: 1476-4687

Kerstin Foitzik ET AL: "Human Scalp Hair Follicles Are Both a Target and a Source of Prolactin, which Serves as an Autocrine and/or Paracrine Promoter of Apoptosis-Driven Hair Follicle Regression", AMERICAN JOURNAL OF PATHOLOGY., vol. 168, no. 3, 1 March 2006 (2006-03-01) , pages 748-756, XP055469860, US ISSN: 0002-9440, DOI: 10.2353/ajpath.2006.050468

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

- 1.** Jak1- og/eller Jak2-inhibitor som velges fra gruppen som består av: AG490 med CAS-nr. 133550-30-8; CYT387 med CAS-nr. 1056634-68-4; SB1518 med CAS-nr. 937272-79-2; TG101348 med CAS-nr. 936091-26-8; BMS-911543 med CAS-nr. 1271022-90-2; WP-1034 med CAS-nr. 857064-42-7; CEP-701 med CAS-nr. 111358-88-4; INCB 018424 med CAS-nr. 941678-49-5; og LY3009104 med CAS-nr. 1187594-09-7 for anvendelse i en fremgangsmåte for behandling av en hårvfallsforstyrrelse valgt fra gruppen som består av alopecia areata og androgenetisk alopecia hos et pattedyrindivid med behov derav.
- 2.** Jak1- og/eller Jak2-inhibitoren for anvendelse ifølge krav 1, hvori behandling oppnås ved å indusere hårvekst hos individet.
- 3.** Jak1- og/eller Jak2-inhibitoren for anvendelse ifølge krav 1 eller 2, hvori inhibitoren er INCB 018424 med CAS-nr. 941678-49-5.
- 4.** Jak1- og/eller Jak2-inhibitoren for anvendelse ifølge krav 1 eller 2, hvori inhibitoren er LY3009104 med CAS-nr. 1187594-09-7.
- 5.** Jak1- og/eller Jak2-inhibitoren for anvendelse ifølge krav 1 eller 2, hvori inhibitoren er AG490 med CAS-nr. 133550-30-8; CYT387 med CAS-nr. 1056634-68-4; SB1518 med CAS-nr. 937272-79-2; TG101348 med CAS-nr. 936091-26-8; BMS-911543 med CAS-nr. 1271022-90-2; WP-1034 med CAS-nr. 857064-42-7 eller CEP-701 med CAS-nr. 111358-88-4.
- 6.** Jak1- og/eller Jak2-inhibitoren for anvendelse ifølge krav 1 eller 2, hvori hårtapforstyrrelsen er alopecia areata.
- 7.** Jak1- og/eller Jak2-inhibitoren for anvendelse ifølge krav 1 eller 2, hvori hårtapforstyrrelsen er androgen alopecia.
- 8.** Jak1- og/eller Jak2-inhibitoren for anvendelse ifølge krav 6, hvori alopecia areata er alopecia totalis eller alopecia universalis.
- 9.** Jak1- og/eller Jak2-inhibitoren for anvendelse ifølge krav 1, hvori Jak1- og/eller Jak2-inhibitoren er i en sammensetning som er egnet for intravenøs, intramuskulær, intra-peritoneal, intradermal, subkutan, oral, nasal, transdermal, topisk, transmukosal, eller

rektal administrering.

- 10.** Jak1- og/eller Jak2-inhibitoren for anvendelse ifølge krav 2, hvori Jak1- og/eller Jak2-inhibitoren er i en sammensætning som er egnet for intravenøs, intramuskulær, intra-peritoneal, intradermal, subkutan, oral, nasal, transdermal, topisk, transmukosal eller rektal administrering.
- 5